<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03016611</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-16-3634</org_study_id>
    <nct_id>NCT03016611</nct_id>
  </id_info>
  <brief_title>Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the efficacy of chewing Ticagrelor versus Prasugrel in ST-elevation Myocardial
      Infarction (STEMI) patients on platelet reactivity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after Ticagrelor/Prasugrel LD</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent of patients with a high residual platelet reactivity (PRU &gt; 208) 1 hour, 4-6 hours after Ticagrelor/Prasugrel LD</measure>
    <time_frame>4-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major, minor, minimal bleeding [ Thrombolysis in Myocardial Infarction (TIMI) criteria] events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of dyspnea and/or symptomatic bradycardia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Chewing Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chewing Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chewing Ticagrelor LD</intervention_name>
    <description>180 mg Chewing Ticagrelor</description>
    <arm_group_label>Chewing Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chewing Prasugrel LD</intervention_name>
    <description>60 mg Chewing Prasugrel</description>
    <arm_group_label>Chewing Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with STEMI

          2. Informed, written consent

        Exclusion Criteria:

          1. Age &lt; 18 years or Age &gt; 75 years

          2. Active bleeding; bleeding diathesis; coagulopathy

          3. Increased risk of bradycardic events

          4. History of gastrointestinal or genitourinary bleeding &lt;2 months

          5. Major surgery in the last 6 weeks

          6. History of intracranial bleeding or structural abnormalities

          7. Suspected aortic dissection

          8. Any other condition that may put the patient at risk or influence study results or
             investigator's opinion (severe hemodynamic instability, unconsciousness, known
             malignancies or other comorbid conditions with life expectancy &lt;1 year)

          9. Administration in the week before the index event of clopidogrel, ticlopidine,
             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or
             fondaparinux.

         10. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers,
             CYP3A with narrow therapeutic windows

         11. Known relevant hematological deviations: Hb &lt;10 g/dl, PLT&lt;100x10^9/l

         12. Use of coumadin derivatives within the last 7 days

         13. Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine

         14. Known severe liver disease, severe renal failure

         15. Known allergy to the study medications

         16. Pregnancy

         17. Human immunodeficiency virus treatment

         18. The use of IIBIIIA receptor antagonists in the 48 hours before enrollment (if
             abciximab use then in the last 14 days).

         19. If the patients cannot sign percutaneous coronary intervention (PCI) informed consent
             for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elad Asher, MD; MHA</last_name>
    <phone>+972-52-6667131</phone>
    <email>el.asher@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Elad Asher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

